Posts

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering – June 24, 2026

on

uniQure Announces Pricing of Upsized $225 Million Public Offering: Details and Highlights

on

Drugmakers must disclose U.S. production plans to qualify for tariff exemptions

on

Novo Nordisk Q1: Pills, Pricing, Payments, Pressure

on

Regeneron Among Remaining Holdouts in Trump's Most-Favored-Nation Drug Pricing Deals

on

GoodRx Expands Access to Eli Lilly's New Oral GLP-1 Foundayo and Zepbound KwikPen with Self-Pay Pricing at Over 70,000 Pharmacies

on

UK Finalises US Pharma Trade Deal Securing Tariff-Free Access for British Medicines

on

Trump Administration's Drug Pricing Reforms and Pharmaceutical Industry Response in 2026

on

Drugmakers with White House MFN Deals Claim Exemption from Proposed Medicare Pricing Tests

on

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

on

PBMs and FTC Battle in Court Over In-House Insulin Pricing Challenge Intensifies

on

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

on

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

on

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

on

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

on

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

on

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

on

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

on

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

on

Pfizer CEO Holds 'Extremely Productive' Talks With Trump Administration Amid MFN Pricing and Tariff Threats

on